centerforbiosimilars10h
3 Ustekinumab Biosimilars Launch on US Market
Three ustekinumab biosimilars enter the US market, expanding access to more affordable options referencing Stelara ...
centerforbiosimilars1d
Lisa Lasita, PharmD, MBA
Study Confirms CT-P42 Therapeutic Equivalence to Reference Aflibercept in DME ...
centerforbiosimilars1d
Josh Canavan, PharmD
Cetuximab Biosimilar Receives NMPA Approval for RAS/BRAF Wild-Type CRC ...
centerforbiosimilars2d
Will the FTC Be More PBM-Friendly Under A Second Trump Administration?
On this episode of Not So Different, we explore the Federal Trade Commission’s (FTC) second interim report on pharmacy ...
centerforbiosimilars2d
Derek Burns, PharmD, MBA, BCPS, BCSCP
Cetuximab Biosimilar Receives NMPA Approval for RAS/BRAF Wild-Type CRC ...
centerforbiosimilars2d
James D. Chambers, PhD, MPharm, MSc
Cetuximab Biosimilar Receives NMPA Approval for RAS/BRAF Wild-Type CRC ...
centerforbiosimilars3d
Travis Brewer
Cetuximab Biosimilar Receives NMPA Approval for RAS/BRAF Wild-Type CRC ...
centerforbiosimilars4d
The Top 5 Biosimilar Articles for the Week of February 17
Number 4: The FDA and European Medicines Agency (EMA) granted approval, with interchangeability in the US, to Samsung Bioepis ...
centerforbiosimilars4d
EC Approves Celltrion Denosumab, Aflibercept Biosimilars
Celltrion expands its reach in Europe, securing marketing authorization from the European Commission (EC) for its denosumab biosimilar candidate (Stoboclo and Osenvelt) and its aflibercept biosimilar ...